All In Biotech

Drug Trial Radar · NCT06316791

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 14, 2021

Primary completion

Dec 13, 2025

Study completion Dec 13, 2025

Sponsor

Lead sponsor
Juventas Cell Therapy Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus nephritis, immune thrombocytopenia), refractory ANCA-associated vasculitis, and refractory dermatomyositis on the basis of standard of care.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • single dose of CNCT19Biological

    Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Experiencing Treatment-Emergent Adverse Events(TEAE)Time frame: Up to 1 year after CNCT19 infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.